Use of genotype frequencies in medicated groups to investigate prescribing practice: APOE and statins as a proof of principle

Clinical Chemistry

Volumn 57, Issue 3, 2011, Pages 502-510

  Davies, Neil M ^a   Windmeijer, Frank ^a   Martin, Richard M ^a   Abdollahi, Mohammad R ^a   Smith, George Davey ^a   Lawlor, Debbie A ^a   Ebrahim, Shah ^b   Day, Ian N M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; APOE GENE; ARTICLE; CLINICAL PRACTICE; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOME ANALYSIS; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PHENOTYPE; PRESCRIPTION;

AGED; APOLIPOPROTEINS E; CHOLESTEROL, LDL; COHORT STUDIES; DRUG PRESCRIPTIONS; ENGLAND; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; MODELS, STATISTICAL; PHYSICIAN'S PRACTICE PATTERNS; POLYMORPHISM, GENETIC;

EID: 79952237154     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.156356     Document Type: Article

References (18)

1. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Day I, Ebrahim S. Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology. PLoS Med 2007;4:e352.
2. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-78.
3. Evans I, Chalmers I, Thornton H. Testing treatments: better research for better healthcare. London: The British Library; 2006. 224 p.
4. Abdollahi MR, Guthrie PAI, Davey Smith G, Lawlor DA, Ebrahim S, Day INM. Integrated single-label liquid-phase assay of APOE codons 112 and 158 and a lipoprotein study in British women. Clin Chem 2006;52:1420-3. (Pubitemid 43956036)
5. Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem 1990;36:15-9.
6. Lawlor DA, Ebrahim S, Davey Smith G. Socioeconomic position in childhood and adulthood and insulin resistance: cross sectional survey using data from British Women's Heart and Health Study. BMJ 2002;325:805.
7. Lawlor DA, Bedford C, Taylor M, Ebrahim S. Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study. J Epidemiol Community Health 2003;57:134-40. (Pubitemid 36160623)
8. Liu HC, Hong CJ, Wang SJ, Fuh JL, Wang PN, Shyu HY, Teng EL. ApoE genotype in relation to AD and cholesterol: a study of 2,326 Chinese adults. Neurology 1999;53:962-6. (Pubitemid 29442110)
9. Haddy N, De Bacquer D, Chemaly MM, Maurice M, Ehnholm C, Evans A, et al. The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on interindividual variation in lipid levels: results from Apo Europe. Eur J Hum Genet 2002;10:841-50. (Pubitemid 36054566)
10. Kaye J. The regulation of direct-to-consumer genetic tests. Hum Mol Genet 2008;17:R180-3.
11. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-13.
12. Donnelly LA, Palmer CNA, Whitley AL, Lang CC, Doney ASF, Morris AD, Donnan PT. Apolipoprotein E genotypes are associated with lipidlowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet Genomics 2008;18:279-87. (Pubitemid 351367521)
13. Humphries SE, Talmud PJ, Hawe E, Bolla M, Day INM, Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 2001;358:115-9. (Pubitemid 32709850)
14. Ye S, Dunleavey L, Bannister W, Day LB, Tapper W, Collins AR, et al. Independent effects of the -219 G>T and epsilon 2/ epsilon 3/ epsilon 4 polymorphisms in the apolipoprotein E gene on coronary artery disease: the Southampton Atherosclerosis Study. Eur J Hum Genet 2003;11:437-43. (Pubitemid 36722262)
15. Packard CJ, Westendorp RGJ, Stott DJ, Caslake MJ, Murray HM, Shepherd J, et al. Association between apolipoprotein E4 and cognitive decline in elderly adults. J Am Geriatr Soc 2007;55:1777-85. (Pubitemid 350043781)
16. Zhao JH, Brunner EJ, Kumari M, Singh-Manoux A, Hawe E, Talmud PJ, et al. APOE polymorphism, socioeconomic status and cognitive function in mid-life - the Whitehall II longitudinal study. Soc Psychiatry Psychiatr Epidemiol 2005;40:557-63. (Pubitemid 41222819)
17. Cumming AM, Robertson FW. Polymorphism at the apoprotein-E locus in relation to risk of coronary disease. Clin Genet 1984;25:310-3. (Pubitemid 14157792)
18. Taylor AE, Guthrie PAI, Davey Smith G, Golding J, Sattar N, Hingorani AD, et al. IQ, educational attainment, memory and plasma lipids: associations with apolipoprotein E genotype in 5995 children. Biol Psychiatry [Epub ahead of print 2011 Jan 5].